Reagenti e strumenti per immunologia, biologia cellulare e biologia molecolare

TBHQ [1948-33-0]

Stampa

Cat# HY-100489-1mL

Size : 10mM/1mL

Marca : MedChemExpress

Richiedere ulteriori informazioni

Description

TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2^[1]. TBHQ (tert-Butylhydroquinone) is also an ERK activator; rescues Dehydrocorydaline (DHC)-induced cell proliferation inhibitionin melanoma^[2].

IC₅₀ & Target^[1]^[2]

Nrf2

ERK

Autophagy

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC₅₀	>100 μM Compound: tBHQ	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 23820128]
HeLa	EC₅₀	>400 μM Compound: TBHQ	Inhibition of Influenza A virus H3N2 A/X-31 hemagglutinin 3 D1122N expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.6 by giemsa staining bas Inhibition of Influenza A virus H3N2 A/X-31 hemagglutinin 3 D1122N expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.6 by giemsa staining bas	[PMID: 31753804]
HeLa	EC₅₀	12 μM Compound: TBHQ	Inhibition of Influenza A virus H3N2 A/X-31 hemagglutinin 3 E572K mutant expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.2 by giemsa staini Inhibition of Influenza A virus H3N2 A/X-31 hemagglutinin 3 E572K mutant expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.2 by giemsa staini	[PMID: 31753804]
HeLa	EC₅₀	9.9 μM Compound: TBHQ	Inhibition of influenza H3N2 A/X-31 hemagglutinin 3 expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.2 by giemsa staining based microscopic Inhibition of influenza H3N2 A/X-31 hemagglutinin 3 expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.2 by giemsa staining based microscopic	[PMID: 31753804]
HepG2	EC₅₀	12.6 μM Compound: t-Butylhydroquinone	Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis	[PMID: 20966043]
HepG2	EC₅₀	2 μM Compound: t-Butylhydroquinone	Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis	[PMID: 20966043]
THP-1	IC₅₀	>100 μM Compound: tBHQ	Cytotoxicity against human THP-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human THP-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35253427]

In Vitro

TBHQ (t-butylhydroquinone; tBHQ; 0-100 μM; 48 hours; H9c2 cells) alone does not affect H9c2 cells viability. Pre-incubation of the H9c2 cells with various concentrations of tBHQ for 24 hours enhances cell viability which is decreased due to exposure to ethanol in a dose-dependent manner. Treatment with tBHQ markedly enhances the viability of H9c2 cardiomyocytes exposed to ethanol^[3].
TBHQ (5 μM; 15 min; H9c2 cells) treatment significantly reduces the amount of apoptotic cells exposed to ethanol^[3].
TBHQ (5 μM; H9c2 cells) pre-treatment markedly inhibites the ethanol-induced increase in caspase-3 and Bax expression, and enhances Bcl-2 expression^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:	H9c2 cells
Concentration:	0 µM, 0.625 µM, 1.25 µM, 2.5 µM, 5 µM, 10 µM, 20 µM, 50 µM and 100 µM
Incubation Time:	48 hours
Result:	Enhanced the viability of H9c2 cardiomyocytes exposed to ethanol.

Apoptosis Analysis^[3]

Cell Line:	H9c2 cells
Concentration:	5 μM
Incubation Time:
Result:	Lowered the amount of apoptotic cells exposed to ethanol.

Western Blot Analysis^[3]

Cell Line:	H9c2 cells
Concentration:	5 μM
Incubation Time:
Result:	Inhibited the ethanol-induced increase in caspase-3 and Bax expression, and enhanced Bcl-2 expression.

In Vivo

TBHQ treatment (50 mg/kg; Intraperitoneal injection; three injections at intervals of 8 h that began 1-h post ICH; CD-1 mice) augments the DNA-Binding activity of Nrf2, attenuates oxidative brain damage and acute neurological deficits afterintracerebral hemorrhage (ICH), attenuates microglial activation with concomitant reduction in the release of proinflammatory cytokine interleukin-1β (IL-1β). TBHQ has the efficacy of post-injury administration in attenuating acute neurological injury after ICH^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male CD-1 mice (8-10 weeks old)^[4]
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection; three injections at intervals of 8 hours that began 1h post ICH.
Result:	The treatment augmented the DNA-binding activity of Nrf2, attenuated brain oxidative damage, attenuated the microglial activation and the expression of IL-1β.

Masse moléculaire

166.22

Formule

C₁₀H₁₄O₂

CAS No.

1948-33-0

Appearance

Solid

Color

White to off-white

SMILES

OC1=CC=C(O)C=C1C(C)(C)C

Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

Solvant et solubilité

In Vitro:

DMSO : ≥ 56.66 mg/mL (340.87 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	6.0161 mL	30.0806 mL	60.1612 mL
5 mM	1.2032 mL	6.0161 mL	12.0322 mL
10 mM	0.6016 mL	3.0081 mL	6.0161 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (15.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (15.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (15.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 20 mg/mL (120.32 mM); Clear solution; Need ultrasonic

Pureté et documentation

Purity: 99.88%

Fiche technique (280 KB) SDS (597 KB)

COA (248 KB) LCMS (93 KB)

Instruction de manipulation (2659 KB)

Références

[1]. Lin-Feng Wang, et al. Tert-butylhydroquinone ameliorates doxorubicin-induced cardiotoxicity by activating Nrf2 and inducing the expression of its target genes. Am J Transl Res. 2015; 7(10): 1724–1735. [Content Brief]

[2]. XIAOJING SHI, et al. Tert-butylhydroquinone attenuates the ethanol-induced apoptosis of and activates the Nrf2 antioxidant defense pathway in H9c2 cardiomyocytes.Int J Mol Med. 2016 Jul; 38(1): 123–130. [Content Brief]

[3]. Hu H, et al. Dehydrocorydaline inhibits cell proliferation, migration and invasion via suppressing MEK1/2-ERK1/2 cascade in melanoma.Onco Targets Ther. 2019 Jul 2;12:5163-5175. [Content Brief]

[4]. Sukumari-Ramesh S, et al. Post-Injury Administration of Tert-butylhydroquinone Attenuates Acute Neurological Injury AfterIntracerebral Hemorrhage in Mice.J Mol Neurosci. 2016 Apr;58(4):525-31. [Content Brief]

Si può anche essere interessati nei seguenti prodotti:

Cat#

Descrizione

Cond.

Priced

T1419-50mg

Azithromycin hydrate [117772-70-0]

50mg

HY-17506A-50mg

Azithromycin (hydrate) [117772-70-0]

50mg

T5364-1ml

TBHQ [1948-33-0]

1mLx10mM(inDMSO)

TBHQ [1948-33-0]

Cat# HY-100489-1mL

Marca : MedChemExpress

TBHQ Related Antibodies

Si può anche essere interessati nei seguenti prodotti: